result outlook expect
summari morn report result
provid outlook quarterli print outlook
mostli anticip believ clear line sight
acceler get offenc make
progress toward goal return weight averag market
growth wamgr consist basi deliv
underli growth guid mid-point
rang appear achiev
growth weight heavili versu fx
headwind eas sell day revers headwind tailwind
net neutral full year get offenc full
bag new product recal alreadi full line
approv product launch see note date
januari rosa tka clearanc round
offer chang assumpt
underli revenu growth adj ep estim
revenu estim account beat
modestli lower fx headwind previous project
ep estim unchang maintain
outperform rate
result driven revenu
y/i y/i ex-fx ahead estim
consensu deliv solid underli
sale growth asiapacif emea
off-set america emea growth benefit rebat
adjust contribut estim emea growth
growth nearli adjust basi region
best perform two year america y/i declin
tough comp prior year quarter overal deliv ex-fx
organ sale growth y/i includ estim
benefit emea rebat adjust came ahead
estim growth organ growth repres deceler
versu expect due follow
factor tough y/i comparison headwind
bone cement issu headwind greater fx
headwind continu make progress quarter
stack growth acceler reflect
improv compani report adjust ep
y/i in-lin estim penni ahead
consensu zbh om estim
lower effect tax rate better higher top-lin led ep
come in-lin
continu page
compani data secur llc estim reuter
ep exclud amort non-recur item
compani data secur llc estim reuter
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
continu previou page
outlook look achiev growth focus may prove conserv
manag provid outlook first time look report revenu growth
rang impli revenu fx expect
headwind would translat top-lin underli growth new estim call
revenu repres underli growth anticip growth back-end
load sell day adjust growth lower-end guidanc rang sequenti
acceler thereaft elsewher manag expect oper margin om
repres margin contract midpoint reflect manufactur sg invest
support new product launch model om lower-end rang
higher level volum ramp tax rate expect flat
y/i net-net look ep y/i full year versu
estim unchang compani plan gener free cash flow
note debt repay remain first use cash zbh net leverag ratio
manag note comfort look target even though laser focus deliv
turnaround
segment result stack follow exceed expect set sport
extrem trauma spine cmf craniomaxillofaci knee dental
slightli better hip slightli sale growth repres y/i ex-fx rate
versu stack follow
knee sale versu compar estim
growth driven sequenti improv asiapacif improv
emea deceler america knee price slightli better sequenti
versu volum slightli lower versu lost share
syk mako quarter offenc yet portfolio product
said compani necessari approv alreadi execut full launch
includ persona famili knee rosa tka rosa platform along other
showcas upcom aao american academi orthoped surgeon medic meet la
vega outlin product uniqu featur call due competit
reason note abil drive procedur effici ceo bryan hanson also note zbh
knee share lag procedur share rosa could meaning bridg gap note
persona uni knee persona cementless alreadi full launch plan get
offenc includ persona revis rosa tka
hip sale versu compar estim
growth driven acceler emea off-set deceler asiapacif
deceler america hip price better versu
volum notabl lower versu littl hip commentari
call believ like experienc competit headwind mako pull
hip possibl leadership posit anterior approach strong market demand
acti stem one-tim rebat adjust like aid result emea quarter
sport medicin extrem trauma set sale versu
compar estim set price continu improv versu
volum versu like saw continu growth across
variou product line steadi suppli sport medicin busi note
indic turnaround us trauma market like aid result segment well
spine craniomaxillofaci cmf sale versu compar
estim spine cmf price versu volum
notabl versu sequenti acceler encourag
zbh sale forc integr dis-synergi spine appear get behind
continu benefit uptak cmf thorac product underli growth also reflect
strongest growth level three year spine continu drag zbh overal perform
manag commit robot platform note rosa applic spine indic
submit fda week rosa tka would anticip approv sometim
near-term devic fulli integr spine cranial applic current
instal base system global manag anticip greater growth spine
busi rel separ record goodwil impair relat spine
asset quarter
dental sale versu compar estim
dental price worsen versu volum improv versu flat
result sequenti deceler work new market strategi within
dental busi made progress past quarter relat portfolio realign sale
reorgan certain geographi
price target nc
price target base approxim cash ep estim risk thesi
includ increas invest slower procedur volum growth price pressur disrupt
integr biomet
zimmer biomet share trade discount large-cap med-tech peer group believ
discount narrow compani benefit leadership new commercially-driven ceo
bryan hanson oper issu resolv pipelin begin fulli appreci
warsaw indiana-bas zimmer biomet hold one world largest orthoped implant
manufactur compani global market leader billion reconstruct orthoped
implant busi hip knee implant togeth account roughli revenu
compani report sale billion
